DE69738776D1 - Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen - Google Patents

Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen

Info

Publication number
DE69738776D1
DE69738776D1 DE69738776T DE69738776T DE69738776D1 DE 69738776 D1 DE69738776 D1 DE 69738776D1 DE 69738776 T DE69738776 T DE 69738776T DE 69738776 T DE69738776 T DE 69738776T DE 69738776 D1 DE69738776 D1 DE 69738776D1
Authority
DE
Germany
Prior art keywords
naip
prevention
iap
treatment
neural diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69738776T
Other languages
English (en)
Inventor
Robert G Korneluk
Alexander E Mackenzie
George S Robertson
D G Xu
S J Krocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Ottawa
Original Assignee
University of Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Ottawa filed Critical University of Ottawa
Application granted granted Critical
Publication of DE69738776D1 publication Critical patent/DE69738776D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69738776T 1996-04-26 1997-04-25 Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen Expired - Fee Related DE69738776D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1735496P 1996-04-26 1996-04-26
US3059096P 1996-11-14 1996-11-14
PCT/IB1997/000721 WO1997040847A1 (en) 1996-04-26 1997-04-25 Therapeutic and drug screening methods for the treatment and prevention of neuronal disease

Publications (1)

Publication Number Publication Date
DE69738776D1 true DE69738776D1 (de) 2008-07-31

Family

ID=26689763

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738776T Expired - Fee Related DE69738776D1 (de) 1996-04-26 1997-04-25 Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen

Country Status (6)

Country Link
US (3) US6159948A (de)
EP (1) EP0840617B1 (de)
AT (1) ATE398459T1 (de)
CA (1) CA2222453C (de)
DE (1) DE69738776D1 (de)
WO (1) WO1997040847A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087173A (en) * 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US6511828B1 (en) 1996-05-31 2003-01-28 Arch Development Corporation Human and drosophila inhibitors of apoptosis proteins (IAPs)
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
PT1049712E (pt) * 1997-08-14 2007-04-30 Pasteur Institut Proteínas híbridas da toxina do tétano que migram retrogradamente e trans - sinapticamente para o snc
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
AU4545299A (en) * 1998-06-02 1999-12-20 Millenium Pharmaceuticals, Inc. Novel molecules of the aip-related protein family and uses thereof
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US20060212025A1 (en) 1998-11-30 2006-09-21 Light Bioscience, Llc Method and apparatus for acne treatment
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6283956B1 (en) 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth
US9192780B2 (en) * 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
JP2004531731A (ja) * 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
US6573300B2 (en) 2001-08-24 2003-06-03 China Medical College Hospital Hydroxyurea treatment for spinal muscular atrophy
AU2003224732A1 (en) * 2002-03-25 2003-10-13 The Trustees Of Boston University Method of using anti-apoptotic factors in gene expression
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
CA2531099A1 (en) * 2003-04-10 2004-10-28 Light Bioscience, Llc Photomodulation methods and devices for regulating cell proliferation and gene expression
CN101247768A (zh) 2003-07-31 2008-08-20 莱特生物科学有限公司 用于光动力学治疗烧伤、创伤和相关皮肤病的系统和方法
WO2006047250A2 (en) 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1955190B1 (de) * 2005-11-10 2018-08-29 In Silico Biosciences, Inc. Verfahren und vorrichtung zur computermodellierung des menschlichen gehirns zur vorhersage von medikamenteneffekten
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332798T2 (de) * 1992-09-14 2004-02-12 The General Hospital Corp., Boston Ikaros: ein regulatorisches gen bei der t-zell differenzierung
DE69534629D1 (de) * 1994-01-18 2005-12-29 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
US6020127A (en) * 1994-10-18 2000-02-01 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
US6156535A (en) * 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
AU6692996A (en) 1995-08-08 1997-03-05 Tularik Inc. Inhibitors of apoptosis
GB9601108D0 (en) * 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)

Also Published As

Publication number Publication date
CA2222453A1 (en) 1997-11-06
US6709866B2 (en) 2004-03-23
EP0840617B1 (de) 2008-06-18
ATE398459T1 (de) 2008-07-15
EP0840617A1 (de) 1998-05-13
CA2222453C (en) 2009-06-30
US20010021699A1 (en) 2001-09-13
US6159948A (en) 2000-12-12
WO1997040847A1 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
DE69738776D1 (de) Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
DE69233478T8 (de) Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
DE60138019D1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69718731D1 (de) Kombinationstherapie für die Behandlung von Psychosen
DE69829412D1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
HK1069767A1 (en) Methods for inhibiting ocular processes
DE69224069D1 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
PT1224205E (pt) Derivados 5-beta-sapogenina e pseudo-sapogenina e sua utilizacao no tratamento de demencia
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE69633336D1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
NO20051664L (no) Behandling av demens og Parkinsons sykdom
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
ATE328887T1 (de) Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee